Hospital

Lauren Dietz, PharmD, highlighted the role of oncology pharmacists in guiding prophylaxis decisions to optimize transplant outcomes.

Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.

Mark Zangardi, PharmD, MS, BCOP, and Amber Cipriani, PharmD, BCOP, discuss the growing role of circulating tumor DNA (ctDNA) testing in oncology, highlighting its applications in early cancer detection, molecular residual disease assessment, and treatment monitoring.

Amir Ali, PharmD, BCOP, and Allison Hsieh, PharmD share insights from their presentation about cytokine release syndrome, ICANS, and CAR T-cell therapy.

Automated diagnosis verification offers a promising alternative for managing the use of GLP-1 medications.

In patients with CKD, there were negative associations between the sodium cotransporter (NCC) and its phosphorylation (pNCC) in urinary extracellular vesicles (uEVs), but further research is needed to confirm these findings in a larger cohort.

The prevalence of hepatitis D virus (HDV) antibody positivity was about 0.24% in patients with chronic hepatitis B virus (HBV).

Michael Arnold, PharmD, discussed the role of oncology pharmacists in enhancing biomarker testing for patients with metastatic colorectal cancer.

Pharmacists play a key role in educating patients and prescribers on the selection, use, and management of GLP-1 receptor agonists in diabetes care.

Matthew Lei, PharmD, BCOP, highlights the value of community, collaboration, and innovation at the HOPA Annual Conference.

Erin Harrell, PharmD, offers insights about managing peripheral neuropathy in patients receiving bortezomib.

Numerical differences were observed as early as Month 1.

Sophie Jabban discusses research presented at the SGO Annual Meeting highlighting significant disparities in MRI access for patients with cervical cancer receiving chemoradiation, with delays linked to both race and insurance status, underscoring systemic barriers that may impact timely treatment.

The approval was based on efficacy and safety data from a randomized, 3-arm, open-label phase 3 CHECKMATE-8HW trial.

Advanced practice provider (APP) care models allow for health systems to better individualize care for patients, effectively meeting their needs.

Kara Melmed, MD, emphasizes the critical importance of rapid, team-based intervention for intracerebral hemorrhage (ICH) patients, with pharmacists playing a key role in blood pressure management.

Pharmacists are essential navigators in the complex landscape of gene therapy.

Enriqueta Felip, MD, PhD, discussed the benefits of subcutaneous pembrolizumab for patients with metastatic non–small cell lung cancer.

Fatty acid metabolism plays a critical role in treatment responses.

Sophie Jabban discusses findings from 2 studies that highlight how geographic location, race, ethnicity, and social determinants of health contribute to delays in initiating chemoradiation for patients with cervical cancer.

The multiple myeloma landscape is evolving, with bispecific T-cell engagers offering hope.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, offers insights for oncology pharmacists treating patients with metastatic esophageal squamous cell carcinoma.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses a case study of a patient with metastatic esophageal squamous cell carcinoma.

Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.

Beth A. Malow, MD, MS, FAAN, said that pharmacists and health care professionals are at the frontlines of collaborating and raising awareness of climate change’s impacts.

Malow also emphasized the importance of staying educated on the potential neurological risks that may occur as a result of climate change.

A significant portion of unvaccinated individuals were open to future vaccination.

The trial showed that adding pelabresib to ruxolitinib improved outcomes in myelofibrosis with manageable side effects.

The new designations span both warm autoimmune hemolytic anemia and IgG4-related disease, 2 rare, immune-mediated conditions that burden patients due to a lack of available treatment options.

BIIB080 is designed to target microtubule-associated protein tau mRNA, aimed to reduce the production of tau protein.